We don’t follow footsteps.
We create the path.

News & events

BLA filing acceptance
Spark Therapeutics announces FDA acceptance of BLA for filing with Priority Review of investigational gene therapy LUXTURNA™ (voretigene neparvovec)

Read More read more

Data published in The Lancet
Spark Therapeutics announces publication in The Lancet of pivotal Phase 3 data at year one for investigational voretigene neparvovec

Read More read more

ISTH 2017
Spark Therapeutics presents updated interim hemophilia B data supporting consistent and sustained response at the ISTH 2017 Congress

Read More read more

“MIT's 50 Smartest Companies”
Spark Therapeutics has been named to MIT Technology Review's "50 Smartest Companies" list in the top 10 for the second year in a row

Read More read more

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-mediated diseases such as hemophilia, and neurodegenerative diseases.

Learn More